Long-term acetyl-L-carnitine treatment in Alzheimer's disease
| Autor: | G. Brambilla, R. Caregnato, Alberto Spagnoli, P. Culotta, C. Bozeglav, S. Scoccia, M. Peruzza, L. Frattura, D. Ieracitano, G. Menasce, E. Parma, M. Alberoni, Marco Stramba-Badiale, A. Belloni, Ugo Lucca, F. Cavazzuti, Mario Comelli, L. Bandera, G. Andreoni, M. R. Inzoli, A. Baiocchi, Gianluigi Forloni, G. Cizza, S. Vitali, M. Favaretto, A. Petrini, A. Salsi, L. Serraiotto, D. De Leo, P. Calogero, C. Negri, A. Longo, G. Santus, U. Senin, Mauro Tettamanti, Pietro Tiraboschi |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Administration Oral Neuropsychological Tests Placebo Apraxia law.invention Cognition Randomized controlled trial Double-Blind Method law Alzheimer Disease Internal medicine Statistical significance medicine Dementia Humans Adverse effect Aged Aged 80 and over Analysis of Variance business.industry Middle Aged medicine.disease Prognosis Surgery Female Neurology (clinical) Alzheimer's disease Verbal memory business Acetylcarnitine |
| Zdroj: | Neurology. 41(11) |
| ISSN: | 0028-3878 |
| Popis: | In a double-blind, placebo-controlled, parallel-group, randomized clinical trial, we studied the efficacy of long-term (1-year) oral treatment with acetyl-L-carnitine in 130 patients with a clinical diagnosis of Alzheimer9s disease. We employed 14 outcome measures to assess functional and cognitive impairment. After 1 year, both the treated and placebo groups worsened, but the treated group showed a slower rate of deterioration in 13 of the 14 outcome measures, reaching statistical significance for the Blessed Dementia Scale, logical intelligence, ideomotor and buccofacial apraxia, and selective attention. Adjusting for initial scores with analysis of covariance, the treated group showed better scores on all outcome measures, reaching statistical significance for the Blessed Dementia Scale, logical intelligence, verbal critical abilities, long-term verbal memory, and selective attention. The analysis for patients with good treatment compliance showed a greater drug benefit than for the overall sample. Reported adverse events were relatively mild, and there was no significant difference between the treated and placebo groups either in incidence or severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|